Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Phillips

Showing results (1-10 of 287) with videos related to

Pageof 29
Sort By:
Current Opinion in HIV and AIDS|April 21, 2011
Modelling the impact of treatment with individual antiretroviralsValentina Cambiano, Andrew N Phillips
AIDS (London, England)|July 7, 2012
The role of individual-based models in understanding the potential impact of antiretroviral therapy for preventionValentina Cambiano, Andrew N Phillips
Current Opinion in HIV and AIDS|June 18, 2009
Predicting the potential benefits of early initiation of ART: time to do a trial to find outAndrew N Phillips, Sean Emery
Current Opinion in Infectious Diseases|March 14, 2009
Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients?Caroline A Sabin, Andrew N Phillips
Current Opinion in HIV and AIDS|April 18, 2009
The CD4 lymphocyte count and risk of clinical progressionAndrew N Phillips, Jens D Lundgren
International Journal of Epidemiology|April 4, 2020
Correlation without a cause: an epidemiological odysseyGeorge Davey Smith, Andrew N Phillips
The Lancet. HIV|March 29, 2025
Modelling study shows staggering impact of HIV funding cutsEuphemia Lindelwe Sibanda, Andrew N Phillips
The Journal of Infectious Diseases|October 15, 2010
Rescue of severely immunocompromised HIV-positive personsJens D Lundgren, Andrew N Phillips
BMJ (Clinical Research Ed.)|January 31, 2004
Indirect comparisons: a novel approach to assessing the effect of anti-HIV drugsJens D Lundgren, Andrew N Phillips
AIDS (London, England)|April 20, 2004
Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infectionAndrew N Phillips, A Sarah Walker
Pageof 29

Showing results (1-10 of 287) with videos related to

Sort By:
Pageof 29
Current Opinion in HIV and AIDS|April 21, 2011
Modelling the impact of treatment with individual antiretroviralsValentina Cambiano, Andrew N Phillips
AIDS (London, England)|July 7, 2012
The role of individual-based models in understanding the potential impact of antiretroviral therapy for preventionValentina Cambiano, Andrew N Phillips
Current Opinion in HIV and AIDS|June 18, 2009
Predicting the potential benefits of early initiation of ART: time to do a trial to find outAndrew N Phillips, Sean Emery
Current Opinion in Infectious Diseases|March 14, 2009
Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients?Caroline A Sabin, Andrew N Phillips
Current Opinion in HIV and AIDS|April 18, 2009
The CD4 lymphocyte count and risk of clinical progressionAndrew N Phillips, Jens D Lundgren
International Journal of Epidemiology|April 4, 2020
Correlation without a cause: an epidemiological odysseyGeorge Davey Smith, Andrew N Phillips
The Lancet. HIV|March 29, 2025
Modelling study shows staggering impact of HIV funding cutsEuphemia Lindelwe Sibanda, Andrew N Phillips
The Journal of Infectious Diseases|October 15, 2010
Rescue of severely immunocompromised HIV-positive personsJens D Lundgren, Andrew N Phillips
BMJ (Clinical Research Ed.)|January 31, 2004
Indirect comparisons: a novel approach to assessing the effect of anti-HIV drugsJens D Lundgren, Andrew N Phillips
AIDS (London, England)|April 20, 2004
Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infectionAndrew N Phillips, A Sarah Walker
Pageof 29